Mirum Pharmaceuticals (MIRM) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Mirum Pharmaceuticals (MIRM) is Neutral.

The composite score behind that read is -0.06, weighing +0.09 of bullish evidence against -0.20 bearish.

Mirum Pharmaceuticals last closed at $86.01, +5.73% on the session.

Against the IVW growth benchmark the position is +4.93% over the forecast window.

The read is built from 15 underlying insights — 3 bullish and 12 bearish.

Agreement across those insights is 80%.

Mirum Pharmaceuticals has no graded predictions yet. We publish our accuracy across thousands of stocks in the open, misses included.

On the fundamentals StockMap ranks Mirum Pharmaceuticals in the 2nd percentile on return on equity, where 100 is best.

Mirum Pharmaceuticals is classified under Health Care / Biotechnology, with a market capitalisation of $5.28B.

StockMap tracks Mirum Pharmaceuticals as the 48th largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Mirum Pharmaceuticals ranks 163rd of 381 in the group, against a group median of -0.08.